-+ 0.00%
-+ 0.00%
-+ 0.00%

Ultragenyx unit Amlogenyx presents at Wells Fargo Healthcare Conference Sept. 8

PUBT·09/02/2026 12:02:22
Listen to the news
Ultragenyx unit Amlogenyx presents at Wells Fargo Healthcare Conference Sept. 8
  • Ultragenyx subsidiary Amlogenyx will present at the Wells Fargo 21st Annual Healthcare Conference in Boston on Sept. 8, 2026.
  • Management presentation scheduled for 3:00 p.m. ET.
  • Amlogenyx is developing AM805, a clinic-ready gene therapy designed to reduce amyloid (Aβ42) accumulation in Alzheimer’s disease.
  • The unit is raising a Series A financing to support Phase 2a clinical proof of concept.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020800PRIMZONEFULLFEED9819926) on September 02, 2026, and is solely responsible for the information contained therein.